175 related articles for article (PubMed ID: 22645357)
1. Inhibition of S-phase kinase-associated protein 2 (Skp2) reprograms and converts diabetogenic T cells to Foxp3+ regulatory T cells.
Wang D; Qin H; Du W; Shen YW; Lee WH; Riggs AD; Liu CP
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9493-8. PubMed ID: 22645357
[TBL] [Abstract][Full Text] [Related]
2. Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhances inhibition of type 1 diabetes by autoantigen-specific regulatory T cells.
Qin H; Wang Z; Du W; Lee WH; Wu X; Riggs AD; Liu CP
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):2016-21. PubMed ID: 21245333
[TBL] [Abstract][Full Text] [Related]
3. Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice.
Amatya C; Radichev IA; Ellefson J; Williams M; Savinov AY
Mol Ther; 2018 Jan; 26(1):184-198. PubMed ID: 28988715
[TBL] [Abstract][Full Text] [Related]
4. Distinct regulatory roles of transforming growth factor-beta and interleukin-4 in the development and maintenance of natural and induced CD4+ CD25+ Foxp3+ regulatory T cells.
Prochazkova J; Fric J; Pokorna K; Neuwirth A; Krulova M; Zajicova A; Holan V
Immunology; 2009 Sep; 128(1 Suppl):e670-8. PubMed ID: 19740328
[TBL] [Abstract][Full Text] [Related]
5. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.
Zuo T; Liu R; Zhang H; Chang X; Liu Y; Wang L; Zheng P; Liu Y
J Clin Invest; 2007 Dec; 117(12):3765-73. PubMed ID: 18008005
[TBL] [Abstract][Full Text] [Related]
6. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model.
Holohan DR; Van Gool F; Bluestone JA
PLoS One; 2019; 14(10):e0217728. PubMed ID: 31647813
[TBL] [Abstract][Full Text] [Related]
7. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice.
Carrier Y; Yuan J; Kuchroo VK; Weiner HL
J Immunol; 2007 Jan; 178(1):179-85. PubMed ID: 17182553
[TBL] [Abstract][Full Text] [Related]
8. β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.
Johnson MC; Garland AL; Nicolson SC; Li C; Samulski RJ; Wang B; Tisch R
Diabetes; 2013 Nov; 62(11):3775-84. PubMed ID: 23884888
[TBL] [Abstract][Full Text] [Related]
9. Differences in T regulatory cells between mouse strains frequently used in immunological research: Treg cell quantities and subpopulations in NOD, B6 and BALB/c mice.
Godoy GJ; Paira DA; Olivera C; Breser ML; Sanchez LR; Motrich RD; Rivero VE
Immunol Lett; 2020 Jul; 223():17-25. PubMed ID: 32330480
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.
Rodriguez S; Abundis C; Boccalatte F; Mehrotra P; Chiang MY; Yui MA; Wang L; Zhang H; Zollman A; Bonfim-Silva R; Kloetgen A; Palmer J; Sandusky G; Wunderlich M; Kaplan MH; Mulloy JC; Marcucci G; Aifantis I; Cardoso AA; Carlesso N
Leukemia; 2020 May; 34(5):1241-1252. PubMed ID: 31772299
[TBL] [Abstract][Full Text] [Related]
11. KAP1 Regulates Regulatory T Cell Function and Proliferation in Both Foxp3-Dependent and -Independent Manners.
Tanaka S; Pfleger C; Lai JF; Roan F; Sun SC; Ziegler SF
Cell Rep; 2018 Apr; 23(3):796-807. PubMed ID: 29669285
[TBL] [Abstract][Full Text] [Related]
12. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
13. FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents.
Ohkura N; Hamaguchi M; Sakaguchi S
Trends Pharmacol Sci; 2011 Mar; 32(3):158-66. PubMed ID: 21237521
[TBL] [Abstract][Full Text] [Related]
14. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
[TBL] [Abstract][Full Text] [Related]
15. Human LAP
Wang H; Song H; Pham AV; Cooper LJ; Schulze JJ; Olek S; Tran DQ
Theranostics; 2019; 9(8):2315-2324. PubMed ID: 31149046
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol.
Schmidt A; Éliás S; Joshi RN; Tegnér J
J Vis Exp; 2016 Dec; (118):. PubMed ID: 28060341
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-dependent induction of CD4⁺CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells.
Carambia A; Freund B; Schwinge D; Heine M; Laschtowitz A; Huber S; Wraith DC; Korn T; Schramm C; Lohse AW; Heeren J; Herkel J
J Hepatol; 2014 Sep; 61(3):594-9. PubMed ID: 24798620
[TBL] [Abstract][Full Text] [Related]
18. Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.
Dwyer CJ; Bayer AL; Fotino C; Yu L; Cabello-Kindelan C; Ward NC; Toomer KH; Chen Z; Malek TR
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259102
[TBL] [Abstract][Full Text] [Related]
19. High Thymic Output of Effector CD4
Zhao Y; Alard P; Kosiewicz MM
J Immunol Res; 2019; 2019():8785263. PubMed ID: 31281853
[TBL] [Abstract][Full Text] [Related]
20. Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes.
Zhen Y; Sun L; Liu H; Duan K; Zeng C; Zhang L; Jin D; Peng J; Ding W; Zhao Y
Cell Mol Immunol; 2012 Jan; 9(1):75-85. PubMed ID: 21983870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
